Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Todd Reilly

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Idrugs : the Investigational Drugs Journal|January 20, 2004
BNP-7787 (BioNumerik/Baxter Oncology/Grelan)R Todd Reilly
Anticancer Research|November 3, 2004
Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesisMingqiang Ren, R Todd Reilly, Nicoletta Sacchi
Breast Disease|February 3, 2005
Augmenting the potency of breast cancer vaccines: combined modality immunotherapyLeisha A Emens, R Todd Reilly, Elizabeth M Jaffee
International Journal of Cancer|May 21, 2009
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunityNaomi Kitamura, Satoshi Murata, Tomoyuki Ueki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 12, 2003
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic miceAnne M Ercolini, Jean-Pascal H Machiels, Yi Cheng Chen, et al.
The Journal of Biological Chemistry|October 28, 2004
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activitiesNaveen K Dakappagari, Kenneth D Lute, Sharad Rawale, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe, Eric R Lutz, Anne M Ercolini, et al.
Cancer Research|May 17, 2008
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse modelHong Song, Karineh Shahverdi, David L Huso, et al.
Cancer Research|January 21, 2006
Ductal access for prevention and therapy of mammary tumorsSatoshi Murata, Scott L Kominsky, Mustafa Vali, et al.
The Journal of Experimental Medicine|May 11, 2005
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini, Brian H Ladle, Elizabeth A Manning, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Idrugs : the Investigational Drugs Journal|January 20, 2004
BNP-7787 (BioNumerik/Baxter Oncology/Grelan)R Todd Reilly
Anticancer Research|November 3, 2004
Sasa health exerts a protective effect on Her2/NeuN mammary tumorigenesisMingqiang Ren, R Todd Reilly, Nicoletta Sacchi
Breast Disease|February 3, 2005
Augmenting the potency of breast cancer vaccines: combined modality immunotherapyLeisha A Emens, R Todd Reilly, Elizabeth M Jaffee
International Journal of Cancer|May 21, 2009
OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunityNaomi Kitamura, Satoshi Murata, Tomoyuki Ueki, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 12, 2003
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic miceAnne M Ercolini, Jean-Pascal H Machiels, Yi Cheng Chen, et al.
The Journal of Biological Chemistry|October 28, 2004
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activitiesNaveen K Dakappagari, Kenneth D Lute, Sharad Rawale, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe, Eric R Lutz, Anne M Ercolini, et al.
Cancer Research|May 17, 2008
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse modelHong Song, Karineh Shahverdi, David L Huso, et al.
Cancer Research|January 21, 2006
Ductal access for prevention and therapy of mammary tumorsSatoshi Murata, Scott L Kominsky, Mustafa Vali, et al.
The Journal of Experimental Medicine|May 11, 2005
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini, Brian H Ladle, Elizabeth A Manning, et al.
Pageof 2